Orasis Pharmaceuticals Announces FDA Approval of QLOSI™
(pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia
Ponte Vedra, FL, October 18, 2023
QLOSI (pronounced CLOH-see) is a prescription eye drop that can be used daily or as needed, up to twice per day. QLOSI demonstrated efficacy 20 minutes after administration and can last up to 8 hours.
John C. Meyer, MD, of The Eye Care Institute and Butchertown Clinical Trials, was the Principal Investigator. Dr. Meyer stated that many presbyopia treatments are available, including glasses, contact lenses, LASIK laser vision correction, and cataract surgery with intraocular lens implants. The availability of an eye drop will be right for patients who wish to improve their vision without needing glasses, contact lenses, or various types of surgery.
This is the 20th FDA approved drug or device for Louisville, KY-based Butchertown Clinical Trials, a division of The Eye Care Institute. Mark Prussian stated each FDA approval is a breakthrough for medicine and for the improvement of the lives of our patients. More treatment options result in a better quality of life for those with this refractive error.”
